PD1/PD-L1 Blockade therapy for cancer:influencing factors,predictive biomarkers and combined treatments / 国际药学研究杂志

Recently,programmed cell death 1/programmed cell death 1 ligand(PD-1/PD-L1)blockade has elicited clinical re-sponses and long-term remissions in a subset of patients with a broad spectrum of cancers. Unfortunately,a substantial number of pa-tients failed to respond to PD1/PD-L1 blockade. In this paper,we summarize our current understanding of the key factors accounting for the difference on treatment,and evaluate the dependability of several potential predictive biomarkers guiding PD1/PD-L1 blockade in cancer therapy. We also discuss a variety of combined treatments based on PD1/PD-L1 blockade.